Podbit · Modern Wisdom
When you're stressed and financially stretched, small purchases become a coping mechanism. Dopamine spikes from buying things provide momentary relief from the anxiety of being broke — which then deepens the financial hole. It's a feedback loop too complex for any political billboard, but possibly one of the key drivers of persistent poverty.
Alzheimer's and other dementias exist on a wide spectrum — from barely detectable impairment to rapid severe decline — and the disease's presentation depends heavily on the individual's brain reserve, comorbidities, and the area of brain affected. Treating it as an all-or-nothing condition misses most of the clinical picture.
The classic amyloid-first model of Alzheimer's pathology is being overturned. Neuroimmunological changes may precede amyloid deposition by years or decades, opening a window for anti-inflammatory intervention as early as your 30s and 40s to prevent the entire cascade from triggering.
Standard cognitive tests like the MoCA or MMSE are nearly useless for highly intelligent patients — many score a perfect 30 well into their condition. Real evaluation requires multi-hour neuropsychological testing, brain blood flow measurement, EEG, specialized MRI, and often amyloid and tau PET scans.
Forgetting names is neurologically normal and almost never a sign of Alzheimer's. The real red flag is difficulty recalling common nouns — struggling to find the word 'chair' or 'book' — because that kind of semantic memory is housed in a different, more diagnostically significant brain region.
Estrogen loss at menopause drives measurable cognitive decline — including memory problems, word-finding difficulties, and executive dysfunction — that is clinically indistinguishable from early Alzheimer's disease. Gayatri Devi has treated multiple women who were misdiagnosed with Alzheimer's when they actually had reversible menopause-related cognitive impairment.
Blood-based Alzheimer's biomarkers are validated against amyloid PET scans — but 25–44% of people over 70 have amyloid in their brains without any dementia. Diagnosing Alzheimer's from a blood test alone risks creating a massive population of 'patients in waiting' who may never develop disease.
Anti-amyloid monoclonal antibodies like lecanemab and donanemab can clear amyloid from the brain, but carry a greater than 40% risk of ARIA in standard protocols for APOE4 carriers. Gayatri Devi developed an ultra-slow titration protocol that reduces this risk to approximately 4%, allowing even high-risk APOE4 homozygotes to access potentially life-changing therapy.
Aducanumab was approved in 2021 against its FDA advisory board's recommendation because clearing amyloid didn't translate to clear clinical benefit in the trials. Gayatri Devi prescribed it anyway, applying a simple personal test: would she want it herself if she had Alzheimer's? Her answer was yes.
Anti-amyloid antibodies clear amyloid not just from brain substrate but also from the walls of small brain arteries. This disrupts vascular integrity, causing fluid leakage (ARIA-E, edema) and then actual blood extravasation (ARIA-H, hemorrhage). In severe cases with blood thinners or large vessel disruption, it can be fatal.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.